We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Danaher Q3 Earnings Surpass Estimates, Diagnostics Sales Up Y/Y
Read MoreHide Full Article
Danaher Corporation’s (DHR - Free Report) third-quarter 2024 adjusted earnings (excluding 59 cents from non-recurring items) of $1.71 per share surpassed the Zacks Consensus Estimate of $1.56. The bottom line declined 0.6% year over year.
Danaher’s reported net sales of $5.8 billion, which beat the consensus estimate of $5.6 billion. The metric increased 3.1% year over year, driven by robust sales in the Diagnostics and Life Sciences segments.
DHR’s core sales increased 0.5%. Acquisitions had a positive impact of 2.5% on quarterly sales, while foreign-currency translations did not have any material impact on the same.
Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.
Segmental Discussion
Revenues from the Life Sciences segment totaled $1.78 billion, up 4.5% year over year. We expected the segment’s revenues to be $1.75 billion. Core sales fell 2% year over year. Acquisitions had a positive impact of 7% on segmental sales, while foreign-currency translations had a negative impact of 0.5%. Adjusted operating profit was $404 million, down 3.1% year over year.
Revenues from the Diagnostics segment totaled $2.36 billion, up 5% year over year. Our estimate for revenues was $2.21 billion. Core sales increased 5% year over year, while foreign currency had no impact on sales. Adjusted operating profit was $664 million, up 12.9% on a year-over-year basis.
Revenues from the Biotechnology segment totaled $1.65 billion, down 0.5% year over year. Our estimate was $1.62 billion. Core sales remained flat year over year, while foreign-currency translations had an adverse impact of 0.5%. Adjusted operating profit was $608 million, down 3.6% year over year.
Danaher Corporation Price, Consensus and EPS Surprise
In the third quarter, Danaher’s cost of sales increased 2% year over year to $2.4 billion. Gross profit of $3.4 billion increased 3.8% year over year. The gross margin was 58.7% compared with 58.2% in the year-ago quarter.
Selling, general and administrative expenses of $2.06 billion recorded an increase of 19.2% on a year-over-year basis. Research and development expenses were $383 million, up 5.7% year over year.
Danaher’s operating profit decreased 19.2% year over year to $958 million. Operating margin contracted to 16.5% from 21.1% in the year-ago quarter.
Balance Sheet and Cash Flow
Exiting the third quarter, DHR had cash and equivalents of $2.6 billion compared with $5.9 billion in 2023-end. Long-term debt was $16.3 billion at the end of the quarter compared with $16.7 billion at the end of December 2023.
Danaher generated net cash of $4.7 billion from operating activities in the first nine months of 2024 compared with $5.5 billion in the previous year’s comparable period. Capital expenditures totaled $876 million in the same period, down 7.7% year over year. Adjusted free cash flow declined 4% year over year to $3.81 billion in the first nine months of 2024.
In the same period, DHR paid out dividends of $573 million, down around 7.7% on a year-over-year basis.
Outlook
For the fourth quarter, Danaher expects adjusted core sales from continuing operations to decline in low-single digits on a year-over-year basis.
The same is also anticipated to decrease in low-single digits on a year-over-year basis in 2024.
Zacks Rank & Stocks to Consider
Danaher presently carries a Zacks Rank #4 (Sell). Some better-ranked companies are discussed below:
MKL delivered a trailing four-quarter average earnings surprise of 35.4%. In the past 60 days, the Zacks Consensus Estimate for Markel’s 2024 earnings has increased 1.8%.
Allegion plc (ALLE - Free Report) presently carries a Zacks Rank of 2. The company delivered a trailing four-quarter average earnings surprise of 10.3%.
In the past 60 days, the Zacks Consensus Estimate for ALLE’s 2024 earnings has remained steady.
Parker-Hannifin Corporation (PH - Free Report) currently carries a Zacks Rank of 2. PH delivered a trailing four-quarter average earnings surprise of 11.2%.
In the past 60 days, the consensus estimate for Parker-Hannifin’s fiscal 2025 (ending June 2025) earnings has increased 0.3%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Danaher Q3 Earnings Surpass Estimates, Diagnostics Sales Up Y/Y
Danaher Corporation’s (DHR - Free Report) third-quarter 2024 adjusted earnings (excluding 59 cents from non-recurring items) of $1.71 per share surpassed the Zacks Consensus Estimate of $1.56. The bottom line declined 0.6% year over year.
Danaher’s reported net sales of $5.8 billion, which beat the consensus estimate of $5.6 billion. The metric increased 3.1% year over year, driven by robust sales in the Diagnostics and Life Sciences segments.
DHR’s core sales increased 0.5%. Acquisitions had a positive impact of 2.5% on quarterly sales, while foreign-currency translations did not have any material impact on the same.
Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.
Segmental Discussion
Revenues from the Life Sciences segment totaled $1.78 billion, up 4.5% year over year. We expected the segment’s revenues to be $1.75 billion. Core sales fell 2% year over year. Acquisitions had a positive impact of 7% on segmental sales, while foreign-currency translations had a negative impact of 0.5%. Adjusted operating profit was $404 million, down 3.1% year over year.
Revenues from the Diagnostics segment totaled $2.36 billion, up 5% year over year. Our estimate for revenues was $2.21 billion. Core sales increased 5% year over year, while foreign currency had no impact on sales. Adjusted operating profit was $664 million, up 12.9% on a year-over-year basis.
Revenues from the Biotechnology segment totaled $1.65 billion, down 0.5% year over year. Our estimate was $1.62 billion. Core sales remained flat year over year, while foreign-currency translations had an adverse impact of 0.5%. Adjusted operating profit was $608 million, down 3.6% year over year.
Danaher Corporation Price, Consensus and EPS Surprise
Danaher Corporation price-consensus-eps-surprise-chart | Danaher Corporation Quote
Margin Profile
In the third quarter, Danaher’s cost of sales increased 2% year over year to $2.4 billion. Gross profit of $3.4 billion increased 3.8% year over year. The gross margin was 58.7% compared with 58.2% in the year-ago quarter.
Selling, general and administrative expenses of $2.06 billion recorded an increase of 19.2% on a year-over-year basis. Research and development expenses were $383 million, up 5.7% year over year.
Danaher’s operating profit decreased 19.2% year over year to $958 million. Operating margin contracted to 16.5% from 21.1% in the year-ago quarter.
Balance Sheet and Cash Flow
Exiting the third quarter, DHR had cash and equivalents of $2.6 billion compared with $5.9 billion in 2023-end. Long-term debt was $16.3 billion at the end of the quarter compared with $16.7 billion at the end of December 2023.
Danaher generated net cash of $4.7 billion from operating activities in the first nine months of 2024 compared with $5.5 billion in the previous year’s comparable period. Capital expenditures totaled $876 million in the same period, down 7.7% year over year. Adjusted free cash flow declined 4% year over year to $3.81 billion in the first nine months of 2024.
In the same period, DHR paid out dividends of $573 million, down around 7.7% on a year-over-year basis.
Outlook
For the fourth quarter, Danaher expects adjusted core sales from continuing operations to decline in low-single digits on a year-over-year basis.
The same is also anticipated to decrease in low-single digits on a year-over-year basis in 2024.
Zacks Rank & Stocks to Consider
Danaher presently carries a Zacks Rank #4 (Sell). Some better-ranked companies are discussed below:
Markel Group Inc. (MKL - Free Report) currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
MKL delivered a trailing four-quarter average earnings surprise of 35.4%. In the past 60 days, the Zacks Consensus Estimate for Markel’s 2024 earnings has increased 1.8%.
Allegion plc (ALLE - Free Report) presently carries a Zacks Rank of 2. The company delivered a trailing four-quarter average earnings surprise of 10.3%.
In the past 60 days, the Zacks Consensus Estimate for ALLE’s 2024 earnings has remained steady.
Parker-Hannifin Corporation (PH - Free Report) currently carries a Zacks Rank of 2. PH delivered a trailing four-quarter average earnings surprise of 11.2%.
In the past 60 days, the consensus estimate for Parker-Hannifin’s fiscal 2025 (ending June 2025) earnings has increased 0.3%.